Illumina Inc
ILMN · What the business does, what can go wrong, and how options sellers approach it
What it does
Illumina makes the instruments, chemicals and software used to read DNA and RNA, a process called sequencing. Its machines are used by research labs, hospitals, drug developers, and clinical testing companies.
Sequencing tools range from high-capacity systems that can read an entire human genome to smaller ones built for narrower tasks, such as screening tumors or tracking viruses. Illumina also sells microarrays, a lower-cost method for checking specific genetic markers.
How it makes money
Illumina sells instruments once, then earns recurring revenue from the consumables (reagent kits and flow cells) that each run uses up. It also earns from services, such as support contracts and sequencing-related offerings.
This is often compared to a razor-and-blade model. Revenue depends on how often customers run samples, not just on how many machines are installed.
Why investors own it
Investors typically view Illumina as a core supplier to genomics, with a large installed base of machines that keeps pulling through consumable purchases. Its sequencing technology is widely used in research and clinical work, so it is often seen as a way to participate in growth in genetic testing, cancer diagnostics, and precision medicine.
What can go wrong
- Research funding and biotech spending can be cyclical, and customers may delay equipment purchases.
- Competitors keep pushing on price and performance, which could pressure margins.
- Regulation, reimbursement rules, and trade or geopolitical tensions can affect demand, especially in clinical markets and in certain countries.
- Acquisitions and antitrust scrutiny have created uncertainty for the company in the past and could again.
- Its growth is tied to the pace of new uses for sequencing, which may arrive slower than expected.
What to watch
- Consumables revenue and instrument placements
- Clinical versus research mix
- Gross margin trends
- Guidance and commentary on customer spending
- Competitive product launches and pricing
- Regulatory or reimbursement decisions affecting genetic testing
- Performance in China and other key international regions
Options income angle
Options on ILMN are generally liquid, with active trading across several expirations, though bid-ask spreads can widen in less popular strikes. Implied volatility tends to rise around earnings, guidance changes, regulatory news, and shifts in sentiment toward life science tools and biotech funding.
One caution for anyone selling premium: the stock can move sharply on earnings or company-specific news, so a short option can lose much more than the premium collected. Elevated implied volatility before events often reflects that risk.
Follow ILMN in Kortex
The Kortex app shows ILMN's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.